Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17984998 | 1.00 | SLC2A1 (0.41) | SLC2A1CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16303327 | 1.00 | SLC2A1 (0.41) | SLC2A1CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16303322 | 0.80 | HRH3 (0.38) | — | |
| SCHEMBL17984992 | 0.80 | HRH3 (0.38) | — | |
| SCHEMBL16293271 | 0.79 | ALDH1A1 (0.37) | — | |
| SCHEMBL15994364 | 0.79 | ALDH1A1 (0.37) | — | |
| SCHEMBL16006890 | 0.79 | ALDH1A1 (0.37) | — | |
| SCHEMBL16303309 | 0.75 | SIRT2 (0.35) | — | |
| SCHEMBL16293555 | 0.75 | SIRT2 (0.35) | — | |
| SCHEMBL16293557 | 0.75 | SIRT2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | claimed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | claimed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | claimed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | SLC2A1 4361/4885CHRNB1 2415/4885CHRNB2 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.